Abstract 316P
Background
Although Olaparib has demonstrated substantial clinical benefits as maintenance therapy in BRCA mutation-carrying women with newly diagnosed advanced ovarian cancer, its effectiveness in patients without BRCA mutations remains under-investigated. This study aims to provide the first evidence on the efficacy of olaparib maintenance therapy in such a context.
Methods
Using real-world data from eleven high-volume tertiary care centers in China, we conducted a retrospective cohort study to assess the efficacy and safety of olaparib maintenance therapy in BRCA wild-type ovarian cancer patients in the first-line setting. Eligible women were identified by medical record review at each institution. The primary objective was the 1-year progression-free survival (PFS) rate. Details of safety profile were also evaluated.
Results
A total of 50 patients with a median age of 54 years were included. Of these patients, 44 (88%) had International Federation of Gynaecology and Obstetrics (FIGO) stage III disease at diagnosis, while 6 (12%) had stage IV disease. The 1-year PFS rate was 75.2% (95% CI, 63.4 to 89.2) and the median PFS was 21.0 months (95% CI, 13.8 to 28.2). All patients received olaparib at a starting dose of 300 mg twice daily and no patients experienced serious adverse events (AEs). Eight (16%) patients had a dose adjustment, but no patients discontinued olaparib treatment due to AEs.
Conclusions
We provide the first evidence that olaparib could be a safe and effective first-line maintenance treatment for women with BRCA wild-type ovarian cancer. These findings propose a new treatment option for this sizable patient subgroup.
Clinical trial identification
NCT05153603.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AZ.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract